Skip to content
  • Tuesday, 27 October 2026
  • 11:30 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna May 4, 2026 0

Researchers from the University of Michigan and the University of California San Diego have published a groundbreaking study identifying the…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.

Dwi Wanna Apr 27, 2026 0

This fundamental discovery, detailed in a collaborative study by researchers from the University of Michigan and the University of California…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna Apr 6, 2026 0

The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…

Read More
Pharmaceutical R&D

Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion, Bolstering Neuroscience Pipeline

Teuku Ryan Apr 2, 2026 0

Eli Lilly and Company announced a significant move to acquire Centessa Pharmaceuticals, a UK-based biopharmaceutical company specializing in neuroscience, in…

Read More
Pharmaceutical R&D

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline

Teuku Ryan Mar 31, 2026 0

TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…

Read More
Pharmaceutical R&D

Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline

Teuku Ryan Mar 28, 2026 0

Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…

Read More
Pharmaceutical R&D

Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases

Teuku Ryan Mar 24, 2026 0

Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna Mar 23, 2026 0

The phenomenon of cancer recurrence remains one of the most significant challenges in modern oncology, particularly in the context of…

Read More

Posts pagination

1 2
First Blueprint of Human Skeletal Development Reveals Origins of Arthritis and Skull ConditionsApplication Note: Optimizing alternative vessel formats for transient protein production in the Expi293 PRO Expression SystemFDA Reverses Course, Agrees to Review Moderna’s mRNA Flu VaccineTWiV 1284: Clinical update with Dr. Daniel Griffin
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ